Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma | Zendy

Krämer Oliver H. | Zendy; Schneider Günter | Zendy

Open Access

Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma

Author(s) -

Krämer Oliver H.,

Schneider Günter

Publication year - 2022

Publication title -

clinical and translational medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.125

H-Index - 1

ISSN - 2001-1326

DOI - 10.1002/ctm2.858

Subject(s) - histone deacetylase , epigenetics , cancer research , histone deacetylase inhibitor , histone , diffuse large b cell lymphoma , medicine , vorinostat , transcription factor , computational biology , lymphoma , biology , genetics , gene

In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine , 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c‐FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetylase inhibitor family.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research